Visual analytics of flight trajectories for uncovering decision making strategies

In air traffic management and control, movement data describing actual and planned flights are used for planning, monitoring and post-operation analysis purposes with the goal of increased efficient utilization of air space capacities (in terms of delay reduction or flight efficiency), without compromising the safety of passengers and cargo, nor timeliness of flights. From flight data, it is possible to extract valuable information concerning preferences and decision making of airlines (e.g. route choice) and air traffic managers and controllers (e.g. flight rerouting or optimizing flight times), features whose understanding is intended as a key driver for bringing operational performance benefits. In this paper, we propose a suite of visual analytics techniques for supporting assessment of flight data quality and data analysis workflows centred on revealing decision making preferences

Analysis of Flight Variability: a Systematic Approach

In movement data analysis, there exists a problem of comparing multiple trajectories of moving objects to common or distinct reference trajectories. We introduce a general conceptual framework for comparative analysis of trajectories and an analytical procedure, which consists of (1) finding corresponding points in pairs of trajectories, (2) computation of pairwise difference measures, and (3) interactive visual analysis of the distributions of the differences with respect to space, time, set of moving objects, trajectory structures, and spatio-temporal context. We propose a combination of visualisation, interaction, and data transformation techniques supporting the analysis and demonstrate the use of our approach for solving a challenging problem from the aviation domain

Dispersive estimates for Schr\"odinger operators with point interactions in R3\mathbb{R}^3

The study of dispersive properties of Schr\"odinger operators with point interactions is a fundamental tool for understanding the behavior of many body quantum systems interacting with very short range potential, whose dynamics can be approximated by non linear Schr\"odinger equations with singular interactions. In this work we proved that, in the case of one point interaction in $\mathbb{R}^3$, the perturbed Laplacian satisfies the same $L^p-L^q$ estimates of the free Laplacian in the smaller regime $q\in[2,3)$. These estimates are implied by a recent result concerning the $L^p$ boundedness of the wave operators for the perturbed Laplacian. Our approach, however, is more direct and relatively simple, and could potentially be useful to prove optimal weighted estimates also in the regime $q\geq 3$.Comment: To appear on: "Advances in Quantum Mechanics: Contemporary Trends and Open Problems", G. Dell'Antonio and A. Michelangeli eds., Springer-INdAM series 201

HIV-1 with Multiple CCR5/CXCR4 Chimeric Receptor Use Is Predictive of Immunological Failure in Infected Children

BACKGROUND: HIV-1 R5 viruses are characterized by a large phenotypic variation, that is reflected by the mode of coreceptor use. The ability of R5 HIV-1 to infect target cells expressing chimeric receptors between CCR5 and CXCR4 (R5(broad) viruses), was shown to correlate with disease stage in HIV-1 infected adults. Here, we ask the question whether phenotypic variation of R5 viruses could play a role also in mother-to-child transmission (MTCT) of HIV-1 and pediatric disease progression. METHODOLOGY/PRINCIPAL FINDINGS: Viral isolates obtained from a total of 59 HIV-1 seropositive women (24 transmitting and 35 non transmitting) and 28 infected newborn children, were used to infect U87.CD4 cells expressing wild type or six different CCR5/CXCR4 chimeric receptors. HIV-1 isolates obtained from newborn infants had predominantly R5(narrow) phenotype (n = 20), but R5(broad) and R5X4 viruses were also found in seven and one case, respectively. The presence of R5(broad) and R5X4 phenotypes correlated significantly with a severe decline of the CD4+ T cells (CDC stage 3) or death within 2 years of age. Forty-three percent of the maternal R5 isolates displayed an R5(broad) phenotype, however, the presence of the R5(broad) virus was not predictive for MTCT of HIV-1. Of interest, while only 1 of 5 mothers with an R5X4 virus transmitted the dualtropic virus, 5 of 6 mothers carrying R5(broad) viruses transmitted viruses with a similar broad chimeric coreceptor usage. Thus, the maternal R5(broad) phenotype was largely preserved during transmission and could be predictive of the phenotype of the newborn's viral variant. CONCLUSIONS/SIGNIFICANCE: Our results show that R5(broad) viruses are not hampered in transmission. When transmitted, immunological failure occurs earlier than in children infected with HIV-1 of R5(narrow) phenotype. We believe that this finding is of utmost relevance for therapeutic interventions in pediatric HIV-1 infectio

2d frustrated Ising model with four phases

In this paper we consider a 2d random Ising system on a square lattice with nearest neighbour interactions. The disorder is short range correlated and asymmetry between the vertical and the horizontal direction is admitted. More precisely, the vertical bonds are supposed to be non random while the horizontal bonds alternate: one row of all non random horizontal bonds is followed by one row where they are independent dichotomic random variables. We solve the model using an approximate approach that replace the quenched average with an annealed average under the constraint that the number of frustrated plaquettes is keep fixed and equals that of the true system. The surprising fact is that for some choices of the parameters of the model there are three second order phase transitions separating four different phases: antiferromagnetic, glassy-like, ferromagnetic and paramagnetic.Comment: 17 pages, Plain TeX, uses Harvmac.tex, 4 ps figures, submitted to Physical Review

Superior efficacy of a human immunodeficiency virus vaccine combined with antiretroviral prevention in simian-human immunodeficiency virus-challenged nonhuman primates

International audienc

HIV-DNA Given with or without Intradermal Electroporation Is Safe and Highly Immunogenic in Healthy Swedish HIV-1 DNA/MVA Vaccinees: A Phase I Randomized Trial

We compared safety and immunogenicity of intradermal (ID) vaccination with and without electroporation (EP) in a phase I randomized placebo-controlled trial of an HIV-DNA prime HIV-MVA boost vaccine in healthy Swedish volunteers.HIV-DNA plasmids encoding HIV-1 genes gp160 subtypes A, B and C; Rev B; Gag A and B and RTmut B were given ID at weeks 0, 6 and 12 in a dose of 0.6 mg. Twenty-five volunteers received vaccine using a needle-free device (ZetaJet) with (n=16) or without (n=9) ID EP (Dermavax). Five volunteers were placebo recipients. Boosting with recombinant MVA-CMDR expressing HIV-1 Env, Gag, Pol of CRF01_AE (HIV-MVA) or placebo was performed at weeks 24 and 40. Nine of the vaccinees received a subtype C CN54 gp140 protein boost together with HIV-MVA.The ID/EP delivery was very well tolerated. After three HIV-DNA immunizations, no statistically significant difference was seen in the IFN-γ ELISpot response rate to Gag between HIV-DNA ID/EP recipients (5/15, 33%) and HIV-DNA ID recipients (1/7, 14%, p=0.6158). The first HIV-MVA or HIV-MVA+gp140 vaccination increased the IFN-γ ELISpot response rate to 18/19 (95%). CD4+ and/or CD8+ T cell responses to Gag or Env were demonstrable in 94% of vaccinees. A balanced CD4+ and CD8+ T cell response was noted, with 78% and 71% responders, respectively. IFN-γ and IL-2 dominated the CD4+ T cell response to Gag and Env. The CD8+ response to Gag was broader with expression of IFN-γ, IL-2, MIP-1β and/or CD107. No differences were seen between DNA vaccine groups. Binding antibodies were induced after the second HIV-MVA+/-gp140 in 93% of vaccinees to subtype C Env, with the highest titers among EP/gp140 recipients.Intradermal electroporation of HIV-DNA was well tolerated. Strong cell- and antibody-mediated immune responses were elicited by the HIV-DNA prime and HIV-MVA boosting regimen, with or without intradermal electroporation use.International Standard Randomised Controlled Trial Number (ISRCTN) 60284968